RuiYi Inc. announced today the appointment of Mark Saad as chief financial officer.
For the past decade, Saad has worked as chief financial officer of San Diego-based Cytori Therapeutics Inc. At RuiYi, he will play a leadership role in executing the company’s growth strategy for global therapeutic needs.
“Mark has a depth of experience in life sciences from his strategic financial and operational leadership at an international public company and from his extensive career in investment banking,” said Paul Grayson, president and CEO of RuiYi. “Mark brings hands-on operating abilities, a significant track record in leading successful financing, (mergers and acquisitions) and license transactions and a broad global business expertise, which will be important for RuiYi’s corporate strategy as we pursue the company’s rapid expansion to become a leading innovator of therapeutic antibodies.”
During his ten years at Cytori, Saad oversaw finance and accounting, business development, legal, human resources, facilities and information technology. He led the raising of more than $250 million through strategic investments, private and marketed equity, debt, mergers and acquisitions and license transactions. Prior to Cytori, Saad served as executive director in the investment banking department at UBS AG, where he was both a calling officer and chief operating officer of the market leading Global Healthcare Group.
RuiYi is headquartered in La Jolla with operations in San Diego and Shanghai. The company is focused on the discovery and development of biologic therapeutics.